GLP-1(7-37)acetate structure
|
Common Name | GLP-1(7-37)acetate | ||
---|---|---|---|---|
CAS Number | 1450806-98-0 | Molecular Weight | 3415.72 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C153H232N40O49 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of GLP-1(7-37)acetateGLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion[1]. |
Name | GLP-1(7-37) acetate |
---|
Description | GLP-1(7-37) acetate is an intestinal insulinotropic hormone that augments glucose induced insulin secretion[1]. |
---|---|
Related Catalog | |
In Vivo | GLP-1(7-37) (0.5, 5 or 50 pmol/min/kg) infused during the second hour of a 2-hour 11-mM hyperglycemic clamp produces a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion in rats[2]. Infusion of GLP-1(7-37) (5 pmol/min/kg) from 1 hour through 7 hours produces a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle in rats with maintained glucose concentration at 11 mM[2]. Animal Model: Male Sprague-Dawley rats weighing 300 to 350 g with glucose IV at a variablerate for 7 hours to maintain plasma glucose concentration at 11 mM[2]. Dosage: 5 pmol/min/kg. Administration: IV from 1 hour through 7 hours[2]. Result: Produced a sustained increase in plasma insulin concentration relative to levels in rats infused with vehicle. Animal Model: Male Sprague-Dawley rats weighing 300 to 350 g with maintained plasma glucose concentration at 11 mM[2]. Dosage: 0.5, 5 or 50 pmol/min/kg. Administration: IV during the second hour of a 2-hour 11-mmol/L hyperglycemic clamp. Result: Produced a dose-related enhancement of the glucose-stimulated increase in plasma insulin concentration and an increased rate of glucose infusion. |
References |
Molecular Formula | C153H232N40O49 |
---|---|
Molecular Weight | 3415.72 |
Storage condition | -20°C |